Logo image of NRSN

NEUROSENSE THERAPEUTICS LTD (NRSN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NRSN - IL0011809592 - Common Stock

1.17 USD
+0.13 (+12.5%)
Last: 11/26/2025, 5:14:53 PM
1.14 USD
-0.03 (-2.56%)
After Hours: 11/26/2025, 5:14:53 PM
Fundamental Rating

0

Taking everything into account, NRSN scores 0 out of 10 in our fundamental rating. NRSN was compared to 533 industry peers in the Biotechnology industry. NRSN has a bad profitability rating. Also its financial health evaluation is rather negative. NRSN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRSN has reported negative net income.
In the past year NRSN has reported a negative cash flow from operations.
In the past 5 years NRSN always reported negative net income.
In the past 5 years NRSN always reported negative operating cash flow.
NRSN Yearly Net Income VS EBIT VS OCF VS FCFNRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of NRSN (-1037.60%) is worse than 97.75% of its industry peers.
Industry RankSector Rank
ROA -1037.6%
ROE N/A
ROIC N/A
ROA(3y)-233.27%
ROA(5y)-219.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRSN Yearly ROA, ROE, ROICNRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRSN Yearly Profit, Operating, Gross MarginsNRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, NRSN has more shares outstanding
Compared to 5 years ago, NRSN has more shares outstanding
NRSN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NRSN Yearly Shares OutstandingNRSN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
NRSN Yearly Total Debt VS Total AssetsNRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NRSN has an Altman-Z score of -81.88. This is a bad value and indicates that NRSN is not financially healthy and even has some risk of bankruptcy.
NRSN has a Altman-Z score of -81.88. This is amonst the worse of the industry: NRSN underperforms 95.12% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -81.88
ROIC/WACCN/A
WACCN/A
NRSN Yearly LT Debt VS Equity VS FCFNRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

NRSN has a Current Ratio of 0.21. This is a bad value and indicates that NRSN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.21, NRSN is doing worse than 94.93% of the companies in the same industry.
A Quick Ratio of 0.21 indicates that NRSN may have some problems paying its short term obligations.
NRSN has a Quick ratio of 0.21. This is amonst the worse of the industry: NRSN underperforms 94.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.21
NRSN Yearly Current Assets VS Current LiabilitesNRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.92% over the past year.
EPS 1Y (TTM)25.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NRSN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.66% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.89%
EPS Next 2Y27.37%
EPS Next 3Y17.95%
EPS Next 5Y50.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRSN Yearly Revenue VS EstimatesNRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NRSN Yearly EPS VS EstimatesNRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NRSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRSN Price Earnings VS Forward Price EarningsNRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRSN Per share dataNRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

NRSN's earnings are expected to grow with 17.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.37%
EPS Next 3Y17.95%

More info and screens

0

5. Dividend

5.1 Amount

NRSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROSENSE THERAPEUTICS LTD

NASDAQ:NRSN (11/26/2025, 5:14:53 PM)

After market: 1.14 -0.03 (-2.56%)

1.17

+0.13 (+12.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04
Earnings (Next)11-26 2025-11-26
Inst Owners1.8%
Inst Owner ChangeN/A
Ins Owners20.48%
Ins Owner ChangeN/A
Market Cap29.30M
Revenue(TTM)N/A
Net Income(TTM)-10.21M
Analysts80
Price Target11.73 (902.56%)
Short Float %1.45%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.86%
PT rev (3m)-17.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1037.6%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-233.27%
ROA(5y)-219.6%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.21
Altman-Z -81.88
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292.8%
EPS Next Y33.89%
EPS Next 2Y27.37%
EPS Next 3Y17.95%
EPS Next 5Y50.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.32%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROSENSE THERAPEUTICS LTD / NRSN FAQ

Can you provide the ChartMill fundamental rating for NEUROSENSE THERAPEUTICS LTD?

ChartMill assigns a fundamental rating of 0 / 10 to NRSN.


Can you provide the valuation status for NEUROSENSE THERAPEUTICS LTD?

ChartMill assigns a valuation rating of 0 / 10 to NEUROSENSE THERAPEUTICS LTD (NRSN). This can be considered as Overvalued.


How profitable is NEUROSENSE THERAPEUTICS LTD (NRSN) stock?

NEUROSENSE THERAPEUTICS LTD (NRSN) has a profitability rating of 0 / 10.


Can you provide the financial health for NRSN stock?

The financial health rating of NEUROSENSE THERAPEUTICS LTD (NRSN) is 0 / 10.